Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 109

  • 1 397 clinical trials
  • 586 recruiting
  • 459 conditions
  • 29 countries

Conditions in this area

459 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis44Glioblastoma41Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Partial seizures19Cognitive disorder18Epilepsy18Giant cell arteritis18Anaesthesia17Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+435

Clinical trials in Nervous system disorders

1 397 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 397 clinical trials

Dementia Alzheimer's type

Not recruiting

Study on the Long-term Safety and Effects of AL002 and Florquinitau F18 in Patients with Alzheimer's Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Florquinitau (18F)
  • Sponsor:Alector LLC

Neoplasm malignant+2

Not recruiting

Study on Larotrectinib for Treating Children with Advanced Solid Tumors with NTRK Fusion

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years
  • Substances:Larotrectinib Sulfate
  • Sponsor:Bayer AG

Piriformis syndrome

Not recruiting

Study on the Effect of Botulinum Toxin Type A and Physiological NaCl 0.9% in Patients with Piriformis Syndrome

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Botulinum Toxin Type A
  • Sponsor:Stichting Alrijne Zorggroep

Multiple sclerosis+1

Not recruiting

Study on the Safety and Effects of Ocrelizumab for Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Methylprednisolone
  • Sponsor:F. Hoffmann-La Roche AG

Neuroblastoma recurrent

Not recruiting

Study of Naxitamab and Sargramostim for High-Risk Neuroblastoma in Patients with Refractory Bone or Bone Marrow Disease

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Naxitamab
  • Sponsor:Y-mAbs Therapeutics A/S

Hypertonic bladder+1

Not recruiting

Study on the Safety and Effectiveness of Mirabegron for Children Aged 6 Months to Under 3 Years with Neurogenic Detrusor Overactivity

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Mirabegron
  • Sponsor:Astellas Pharma Global Development Inc.

Spinal muscular atrophy

Not recruiting

Study on the Safety and Effects of Risdiplam for Adults and Children with Spinal Muscular Atrophy

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Risdiplam
  • Sponsor:F. Hoffmann-La Roche AG

Gaucher's disease type III+1

Not recruiting

Study of Venglustat and Imiglucerase for Adult Patients with Gaucher Disease TYPE 3

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Imiglucerase
  • Sponsor:Genzyme Corp.

Becker's muscular dystrophy

Not recruiting

Study on the Long-term Effects of EDG-5506 for Adults and Adolescents with Becker Muscular Dystrophy

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:EDG-5506
  • Sponsor:Edgewise Therapeutics Inc.

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Sodium Cromoglicate for Treating Fatigue in Multiple Sclerosis Patients

Registered drug
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Sodium Cromoglicate
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Clinico San Carlos

Multiple sclerosis+2

Not recruiting

Study on the Effectiveness and Safety of Ocrelizumab, Methylprednisolone, and Diphenhydramine Hydrochloride in Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Methylprednisolone
  • Sponsor:F. Hoffmann-La Roche AG

Migraine+2

Not recruiting

Study on Long-Term Safety of Atogepant for Preventing Migraine in Patients with Chronic or Episodic Migraine

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Atogepant
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride71 clinical trialsTemozolomide38 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide24 clinical trialsParacetamol24 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trialsCarboplatin14 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.